• FDA halts Xencor’s study of XmAb14045 following deaths pharmaceutical-technology
    February 22, 2019
    California-based Xencor has announced the US Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase I trial of its acute myeloid leukaemia drug XmAb14045 following the deaths of two participants....
PharmaSources Customer Service